- Email: [email protected]
S2213-8587(17)30033-5
Corrections
Correction to Lancet Diabetes Endocrinol 2017: 5: 125–33
Correction to Lancet Diabetes Endocrinol 2017; 5: 240–41
Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2017: 5: 125–33—In the Summary and Methods (Outcomes) section, the timeframe for the measurement of daily blood glucose concentrations was incorrectly stated as the first 10 days of therapy. The correct timeframe was the duration of the hospital stay, up to 10 days. In addition, the endpoint of uncontrolled glycaemia leading to treatment failure should have been defined as a post-hoc endpoint. These corrections have been made to the online version as of April 20, 2017.
George K Dimitriadis, Harpal S Randeva, Alexander D Miras. Microvascular complications after metabolic surgery. Lancet Diabetes Endocrinol 2017; 5: 240–41—In this linked Comment, reference number 5 (Cohen et al, BMJ Open 2017) was listed in the reference list but not cited in the text. This reference should have been omitted from the Comment and the subsequent references renumbered accordingly. This correction has been made to the online version as of April 20, 2017.
Correction to Lancet Diabetes Endocrinol 2017: 5: 174–83 Olbers T, Beamish AJ, Gronowitz E, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. Lancet Diabetes Endocrinol 2017; 5: 174–83—The final sentence of the Declaration of interests statement should read “EG, AJB, C-EF, JD, GB, KE, PF, GG, JK, SM, and MP declare no competing interests”. This correction has been made to the online version as of April 20, 2017.
Correction to Lancet Diabetes Endocrinol 2017; published online Jan 23. http://dx.doi. org/10.1016/S22138587(17)30014-1 Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 2017; published online Jan 23. http://dx.doi.org/10.1016/ S2213-8587(17)30014-1—In this Review, the following sentence in the second paragraph of the section titled “Neuroendocrine and metabolic responses to exercise” should read as follows: “During predominantly anaerobic activities such as sprinting,27 and during a high intensity interval training session,28 circulating insulin
www.thelancet.com/diabetes-endocrinology Vol 5 May 2017
concentrations do not decrease as markedly as in purely aerobic activities, in part because the duration of activity is typically shorter.” This correction has been made to the online version as of March 10, 2017.
Correction to Lancet Diabetes Endocrinol 2017; published online Jan 25. http://dx.doi. org/10.1016/S22138587(17)30033-5 Standl E, Schnell O, McGuire K, Ceriello A, Rydén L. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol 2017; published online Jan 25. http://dx.doi.org/10.1016/ S2213-8587(17)30033-5—In table 4, the entries stating “Add-on to maximally tolerated statin dose if failing to reach <1·8 mg/dL” should have stated “Add-on to maximally tolerated statin dose if failing to reach <1·8 mmol/L.” In Figure 1, the p values for EMPA-REG OUTCOME and SUSTAIN 6 regarding primary composite MACE outcome have been corrected from <0·001 (testing for non-inferiority) for both entries to 0·04 for EMPA-REG OUTCOME and 0·02 for SUSTAIN 6 (testing for inferiority). This correction has been made to the online version as of April 3, 2017.
Published Online April 3, 2017 http://dx.doi.org/10.1016/ S2213-8587(17)30106-7
Published Online March 10, 2017 http://dx.doi.org/10.1016/ S2213-8587(17)30086-4
e3
Correction to Lancet Diabetes Endocrinol 2017: 5: 125–33
Correction to Lancet Diabetes Endocrinol 2017; 5: 240–41
Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2017: 5: 125–33—In the Summary and Methods (Outcomes) section, the timeframe for the measurement of daily blood glucose concentrations was incorrectly stated as the first 10 days of therapy. The correct timeframe was the duration of the hospital stay, up to 10 days. In addition, the endpoint of uncontrolled glycaemia leading to treatment failure should have been defined as a post-hoc endpoint. These corrections have been made to the online version as of April 20, 2017.
George K Dimitriadis, Harpal S Randeva, Alexander D Miras. Microvascular complications after metabolic surgery. Lancet Diabetes Endocrinol 2017; 5: 240–41—In this linked Comment, reference number 5 (Cohen et al, BMJ Open 2017) was listed in the reference list but not cited in the text. This reference should have been omitted from the Comment and the subsequent references renumbered accordingly. This correction has been made to the online version as of April 20, 2017.
Correction to Lancet Diabetes Endocrinol 2017: 5: 174–83 Olbers T, Beamish AJ, Gronowitz E, et al. Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study. Lancet Diabetes Endocrinol 2017; 5: 174–83—The final sentence of the Declaration of interests statement should read “EG, AJB, C-EF, JD, GB, KE, PF, GG, JK, SM, and MP declare no competing interests”. This correction has been made to the online version as of April 20, 2017.
Correction to Lancet Diabetes Endocrinol 2017; published online Jan 23. http://dx.doi. org/10.1016/S22138587(17)30014-1 Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol 2017; published online Jan 23. http://dx.doi.org/10.1016/ S2213-8587(17)30014-1—In this Review, the following sentence in the second paragraph of the section titled “Neuroendocrine and metabolic responses to exercise” should read as follows: “During predominantly anaerobic activities such as sprinting,27 and during a high intensity interval training session,28 circulating insulin
www.thelancet.com/diabetes-endocrinology Vol 5 May 2017
concentrations do not decrease as markedly as in purely aerobic activities, in part because the duration of activity is typically shorter.” This correction has been made to the online version as of March 10, 2017.
Correction to Lancet Diabetes Endocrinol 2017; published online Jan 25. http://dx.doi. org/10.1016/S22138587(17)30033-5 Standl E, Schnell O, McGuire K, Ceriello A, Rydén L. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol 2017; published online Jan 25. http://dx.doi.org/10.1016/ S2213-8587(17)30033-5—In table 4, the entries stating “Add-on to maximally tolerated statin dose if failing to reach <1·8 mg/dL” should have stated “Add-on to maximally tolerated statin dose if failing to reach <1·8 mmol/L.” In Figure 1, the p values for EMPA-REG OUTCOME and SUSTAIN 6 regarding primary composite MACE outcome have been corrected from <0·001 (testing for non-inferiority) for both entries to 0·04 for EMPA-REG OUTCOME and 0·02 for SUSTAIN 6 (testing for inferiority). This correction has been made to the online version as of April 3, 2017.
Published Online April 3, 2017 http://dx.doi.org/10.1016/ S2213-8587(17)30106-7
Published Online March 10, 2017 http://dx.doi.org/10.1016/ S2213-8587(17)30086-4
e3